AU2021380319B2 - Pharmaceutical composition for oral administration of edaravone and method of administering same - Google Patents
Pharmaceutical composition for oral administration of edaravone and method of administering same Download PDFInfo
- Publication number
- AU2021380319B2 AU2021380319B2 AU2021380319A AU2021380319A AU2021380319B2 AU 2021380319 B2 AU2021380319 B2 AU 2021380319B2 AU 2021380319 A AU2021380319 A AU 2021380319A AU 2021380319 A AU2021380319 A AU 2021380319A AU 2021380319 B2 AU2021380319 B2 AU 2021380319B2
- Authority
- AU
- Australia
- Prior art keywords
- administration
- meal
- edaravone
- hours
- consumption
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2025203773A AU2025203773A1 (en) | 2020-11-12 | 2025-05-22 | Pharmaceutical composition for oral administration of edaravone and method of administering same |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020188514 | 2020-11-12 | ||
| JP2020-188514 | 2020-11-12 | ||
| PCT/JP2021/041673 WO2022102737A1 (ja) | 2020-11-12 | 2021-11-12 | エダラボン経口投与用医薬組成物およびその投与方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025203773A Division AU2025203773A1 (en) | 2020-11-12 | 2025-05-22 | Pharmaceutical composition for oral administration of edaravone and method of administering same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021380319A1 AU2021380319A1 (en) | 2023-06-22 |
| AU2021380319B2 true AU2021380319B2 (en) | 2025-03-20 |
Family
ID=81602356
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021380319A Active AU2021380319B2 (en) | 2020-11-12 | 2021-11-12 | Pharmaceutical composition for oral administration of edaravone and method of administering same |
| AU2025203773A Pending AU2025203773A1 (en) | 2020-11-12 | 2025-05-22 | Pharmaceutical composition for oral administration of edaravone and method of administering same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025203773A Pending AU2025203773A1 (en) | 2020-11-12 | 2025-05-22 | Pharmaceutical composition for oral administration of edaravone and method of administering same |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11911366B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4245303A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JPWO2022102737A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230098267A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116761601A (cg-RX-API-DMAC7.html) |
| AR (1) | AR124062A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021380319B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198014A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302533A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202228678A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022102737A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024036261A2 (en) * | 2022-08-10 | 2024-02-15 | Kpr U.S., Llc | Occlusion detection system and method for a flow control apparatus |
| EP4559463A1 (en) * | 2023-11-23 | 2025-05-28 | Ferrer Internacional, S.A. | Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190083463A1 (en) * | 2016-03-16 | 2019-03-21 | Suzhou Auzone Biological Technology Co., Ltd. | Edaravone dosage form |
| US20190328712A1 (en) * | 2017-01-17 | 2019-10-31 | Treeway Tw001 B.V. | Treatment comprising oral or gastric administration of edaravone |
| WO2020091036A1 (ja) * | 2018-11-02 | 2020-05-07 | 田辺三菱製薬株式会社 | 経口投与用エダラボン懸濁剤 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61263917A (ja) | 1985-05-20 | 1986-11-21 | Mitsubishi Yuka Yakuhin Kk | 脳機能正常化剤 |
| JPH0531523A (ja) | 1991-07-26 | 1993-02-09 | Aichi Steel Works Ltd | ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置 |
| ES2248144T3 (es) | 2000-10-24 | 2006-03-16 | Mitsubishi Pharma Corporation | Medicamentos para tratar la esclerosis lateral amiotrofica (ela). |
| CN110381923A (zh) * | 2017-01-17 | 2019-10-25 | 萃微Tw001公司 | 包括肠内施用依达拉奉的医学治疗 |
| JP7012792B2 (ja) | 2020-08-06 | 2022-01-28 | 株式会社 ディー・エヌ・エー | 動画を配信するためのシステム、方法、及びプログラム |
| US12194025B2 (en) | 2020-11-12 | 2025-01-14 | Mitsubishi Tanabe Pharma Corporation | Pharmaceutical composition for oral administration of edaravone and method of administering same |
-
2021
- 2021-11-12 JP JP2022562195A patent/JPWO2022102737A1/ja active Pending
- 2021-11-12 AR ARP210103147A patent/AR124062A1/es unknown
- 2021-11-12 AU AU2021380319A patent/AU2021380319B2/en active Active
- 2021-11-12 CN CN202180075839.XA patent/CN116761601A/zh active Pending
- 2021-11-12 EP EP21891982.7A patent/EP4245303A4/en active Pending
- 2021-11-12 CA CA3198014A patent/CA3198014A1/en active Pending
- 2021-11-12 TW TW110142253A patent/TW202228678A/zh unknown
- 2021-11-12 KR KR1020237017986A patent/KR20230098267A/ko not_active Ceased
- 2021-11-12 WO PCT/JP2021/041673 patent/WO2022102737A1/ja not_active Ceased
- 2021-11-12 IL IL302533A patent/IL302533A/en unknown
- 2021-12-29 US US17/564,538 patent/US11911366B2/en active Active
-
2023
- 2023-12-28 US US18/398,241 patent/US12478611B2/en active Active
-
2025
- 2025-01-07 JP JP2025002313A patent/JP2025061070A/ja active Pending
- 2025-05-22 AU AU2025203773A patent/AU2025203773A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190083463A1 (en) * | 2016-03-16 | 2019-03-21 | Suzhou Auzone Biological Technology Co., Ltd. | Edaravone dosage form |
| US20190328712A1 (en) * | 2017-01-17 | 2019-10-31 | Treeway Tw001 B.V. | Treatment comprising oral or gastric administration of edaravone |
| WO2020091036A1 (ja) * | 2018-11-02 | 2020-05-07 | 田辺三菱製薬株式会社 | 経口投与用エダラボン懸濁剤 |
Non-Patent Citations (1)
| Title |
|---|
| Takei, K et al., 'Radicava (edaravone) for Amyotrophic Lateral Slerosis: New Formulation and Its Development Plan (P1.4-014)', Neurology, 2019, vol. 92, no. 15 supplement. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US12478611B2 (en) | 2025-11-25 |
| TW202228678A (zh) | 2022-08-01 |
| US20220142982A1 (en) | 2022-05-12 |
| JPWO2022102737A1 (cg-RX-API-DMAC7.html) | 2022-05-19 |
| IL302533A (en) | 2023-07-01 |
| US11911366B2 (en) | 2024-02-27 |
| CN116761601A (zh) | 2023-09-15 |
| AU2025203773A1 (en) | 2025-06-12 |
| WO2022102737A1 (ja) | 2022-05-19 |
| KR20230098267A (ko) | 2023-07-03 |
| US20240173297A1 (en) | 2024-05-30 |
| AR124062A1 (es) | 2023-02-08 |
| EP4245303A4 (en) | 2024-10-09 |
| CA3198014A1 (en) | 2022-05-19 |
| EP4245303A1 (en) | 2023-09-20 |
| JP2025061070A (ja) | 2025-04-10 |
| AU2021380319A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2025203773A1 (en) | Pharmaceutical composition for oral administration of edaravone and method of administering same | |
| US12527769B2 (en) | Pharmaceutical composition for oral administration of edaravone and method of administering same | |
| BRPI0707277B1 (pt) | Composição, uso da mesma,e , formulação famacêutica | |
| EP2754440B1 (en) | Medicinal agent for treating amyotrophic lateral sclerosis or preventing progression of phase of amyotrophic lateral sclerosis | |
| US20150320712A1 (en) | Nutritional Composition for Gastrostomy-Tube Patients | |
| US12491178B2 (en) | Stable pharmaceutical compositions of edaravone | |
| CN109922801A (zh) | 甲硝唑和巴氯芬的混悬剂和稀释剂 | |
| BR112017027636B1 (pt) | Composições nutricionais líquidas ou semilíquidas e composições nutricionais | |
| EP4559463A1 (en) | Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders | |
| US12558347B2 (en) | Cevimeline liquid formulations | |
| WO2021079987A1 (ja) | 筋質向上剤 | |
| US20260102351A1 (en) | Lyophilized formulation of crofelemer and methods of treatment using the same | |
| JP2010265186A (ja) | 貧血予防用組成物 | |
| US20260027067A1 (en) | Trientine liquid dosage forms | |
| CN116763726A (zh) | 一种盐酸西替利嗪口服溶液及其制备方法 | |
| KR20160004482A (ko) | 몬테루카스트 또는 이의 약제학적으로 허용가능한 염의 경구투여용 액상제제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| HB | Alteration of name in register |
Owner name: TANABE PHARMA CORPORATION Free format text: FORMER NAME(S): MITSUBISHI TANABE PHARMA CORPORATION |